PTO granted a patent that claims gene inactivation by the use of chimeric restriction endonucleases to the Pasteur Institute and Boston Children's Hospital.

Scientists figured out ways to use a chimeric antigen receptor, or CAR, to reprogram T cells to recognize the protein and kill the cancer.

A new therapy, dubbed CAR T for "chimeric antigen receptor T cell," is the next generation of immunotherapy.